ACT Brief: Site Cash Runway and Payment Infrastructure Priority, Biomarker Cut-Off Selection and Disparities, and Batch Failure Prevention Systems

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part five and final segment of his interview, Patrick Mizer, chief technology officer at Ledger Run, addresses the reality that 80% of sites operate on six months or less of cash. Growing investment in agentic AI and workflow modernization signals that the industry is finally starting to treat payment infrastructure as the priority it deserves rather than a back-office commodity.
• In a new contributed article from ICON, Peter Schüler, MD, and Jack L. Martin, MD, examined how biomarker-informed trial enrollment appears straightforward for identifying responders but risks excluding viable patients when sponsors fail to account for demographic variation in cut-off selection and composite biomarker complexity. Failures to distinguish correlation from causality can exacerbate health disparities and potentially compromise regulatory approval.
• In a new contributed article from Pharmaceutical Executive, Israel Ortiz discussed how biopharma batch failures average one every 40 weeks due to contamination, operator error, and equipment failure, each costing millions in lost product and investigation time. Predictive maintenance and connected facility monitoring using advanced sensors and analytics are becoming critical quality levers as manufacturers face mounting cost and regulatory pressures.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.